Papers found in Diabetes

Total and free testosterone concentrations are strongly influenced by age and central obesity in men with type 1 and type 2 diabetes but correlate weakly with symptoms of androgen deficiency and diabe

Testosterone levels are commonly lowered in men with diabetes, but it is unclear how these relate to symptoms of hypogonadism and quality of life. We sought to investigate the relationship between testosterone levels, symptoms of androgen deficiency, erectile function and quality of life in men with type 1 and type 2 diabetes: Testosterone levels are commonly lowered in men with diabetes, but it is unclear how these relate to symptoms of hypogonadism and quality of life. We sought to investigate the relationship between testosterone levels, symptoms of androgen deficiency, erectile function and quality of life in men with type 1 and type 2 diabetes: Biswas M, Hampton D, Newcombe RG, Rees DA.

Year of publication: 2012

Hormonal association and sexual dysfunction in patients with impaired fasting glucose: a cross-sectional and longitudinal study

The category of impaired fasting glucose (IFG) denotes a state of nondiabetic hyperglycemia, considered a risk factor for the further development of diabetes mellitus (DM) and cardiovascular (CV) diseases.AIMThe aim of the present study is to evaluate the impact of IFG on sexual health in men. In addition, its effect on CV morbidity and mortality will also be addressed.METHODSA consecutive series of 3,451 men (mean age 57.3 -¦ 10.1 years) attending our outpatient clinic for sexual dysfunction was retrospectively studied.

Year of publication: 2012

Evaluations of total and bioavailable testosterone levels in patients with different metabolic disorders

Patients with type 2 diabetes (DM2) have lower testosterone (T) levels and higher prevalence of hypogonadism. Aims: 1) evaluate total (TT) and bioavailable T (BT) levels in patients with DM2 and subjects without DM2; 2) evaluate TT and BT levels in patients with DM2, metabolic syndrome (MS), insulin resistance (IR) and normal subjects, and 3) assess levels of TT and BT according to DM2 metabolic control. Methods: We included 67 patients with DM2 and 92 non-diabetic subjects: 44 with MS, 24 with IR and 24 normal.

Year of publication: 2012

Important effects of visceral obesity and insulin resistance on decreased testosterone, erectile dysfunction and non-alcoholic fat liver disease

Abstract Background: Visceral obesity, which in fact is a metabolic syndrome (MS), is related to decreased testosterone and sex hormone-binding globulin (SHBG) in adults. Insulin resistance (IR) results in fat deposition in the liver and occurrence of non-alcoholic fat liver disease(NAFLD). Objective: In this we examined testosterone relationship with abdominal obesity, MS, IR and NAFLD in obese pre-diabetic patients, sex hormones in obese young males and correlations with visceral obesity, lipid status and blood pressure. Design: Cross-sectional study. Methods: The study included 114 obese and impaired glucose tolerance (IGT) patients (age>45) and 44 obese male individuals (age16- 30) classified into two groups: I-with low testosterone <12.0nmol/l; II-with testosterone ëÑ12,0nmol/

Year of publication: 2012

Long-term testosterone improves all the domains of metabolic syndrome.

Testosterone replacement therapy in patients with Late Onset Hypogonadism (LOH) improves comorbidities. We hypothesize that long term testosterone improves the domains of metabolic syndrome. METHODS: As of November of 2004, 261 patients diagnosed with LOH were recruited in 3 centers in Germany for long-term testosterone replacement therapy. Men with a total testosterone level of ëñ3.5 ng/ml and symptoms of erectile dysfunction (IIEF-5< 21) met the inclusion criteria. Long acting intramuscular (IM) Testosterone Undecanoate 1000mg was given on day 1, then 6 weeks post diagnosis of LOH and every 3 months thereafter. The mean follow up time was 4.25 years. Data was collected periodically

Year of publication: 2012

Metabolic syndrome comorbidity in a cohort of 1094 men with low testosterone levels

Objective: To determine the prevalence and risk factors for Metabolic Syndrome (MS) in a cohort of men with low testosterone (T) levels. Methods: A multi-centre, cross-sectional study recruited 1094 consecutive men older than 45 years old with low T levels (<12 nmol/L).

Year of publication: 2012

Associations of sex hormone-binding globulin and testosterone with diabetes among men and women

Associations of sex hormone-binding globulin and testosterone with diabetes among men and women (the Saku Diabetes study): A case control study.

Year of publication: 2012

Impaired postprandial glucose but not impaired fasting glucose is associated with low serum testosterone levels.

Objective: We aimed to investigate whether pre-diabetic states, impaired fasting glucose (IFG) and impaired glucose tolerance (IGT), are associated with androgen deficiency. Methods: The prospective cohort study includes 774 men (aged 41 to 86) undergoing screening androgen deficiency during 2009.

Year of publication: 2012

Poor glycemic control is a risk for low testosterone in type 2 diabetic men with erectile dysfunction

Men with type 2 diabetes mellitus (DM) are associated with a high risk for erectile dysfunction (ED) as well as low testosterone levels. The study investigated the risk factors for hypogonadism in men with DM associated with erectile dysfunction (DMED)

Year of publication: 2012

Total testosterone may not decline with ageing in Korean men aged 40 years or older

Objective: It is generally believed that gonadal function in men declines with ageing. However, observations on ageing-related decrease in total testosterone (TT) are not consistent. The aim of this study is to examine the ageing-related changes of testosterone and to investigate the influence of the ageing-related factors on TT

Year of publication: 2012

Testosterone and obesity-an intimate partnership

Obesity is a worldwide and challenging problem, negatively affecting every aspect of health. While treatment seems obvious: to limit energy intake, this approach appears overwhelmingly unsuccessful. Limiting food intake alone leads to loss of lean body mass which can be prevented by combining it with (moderate) exercise, maintaining lean body mass and improving insulin sensitivity, but experience teaches that this approach is equally unsuccessful. Methods: A review of the literature on the role of testosterone in the etiology and potential treatment of obesity. The latter aspect is supported by data from ongoing studies in three independent cohorts of men who have been treated for up to 15 years with testosterone

Year of publication: 2012

Type 2 diabetes mellitus and testosterone: a meta-analysis study.

Several studies suggest that type 2 diabetes mellitus (T2DM) is often associated with male hypogonadism. Despite the well-known link, the role of testosterone replacement therapy (TRT) in T2DM has not been completely clarified. The aim of the present study was to analyse systematically the relationship between androgen levels and T2DM by reviewing and meta-analysing available prospective and cross-sectional studies. In addition, a specific meta-analysis on the metabolic effects of TRT in available randomized clinical trials (RCTs) was performed.

Year of publication: 2011

Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study)

This study evaluated the effects of testosterone replacement therapy (TRT) on insulin resistance, cardiovascular risk factors, and symptoms in hypogonadal men with type 2 diabetes and/or metabolic syndrome (MetS).

Year of publication: 2011

The role of testosterone in the etiology and treatment of obesity, the metabolic syndrome, and diabetes mellitus type 2.

Obesity has become a major health problem. Testosterone plays a significant role in obesity, glucose homeostasis, and lipid metabolism. The metabolic syndrome is a clustering of risk factors predisposing to diabetes mellitus type 2, atherosclerosis, and cardiovascular morbidity and mortality. The main components of the syndrome are visceral obesity, insulin resistance, glucose intolerance, raised blood pressure and dyslipidemia (elevated triglycerides, low levels of high-density lipoprotein cholesterol), and a proinflammatory and thrombogenic state. Cross-sectional epidemiological studies have reported a direct correlation between plasma testosterone and insulin sensitivity, and low testosterone levels are associated with an increased risk of type 2 diabetes mellitus, dramatically illustrated by androgen deprivation in men with prostate carcinoma. Lower total testosterone and sex hormone-binding globulin (SHBG) predict a higher incidence of the metabolic syndrome. Administration of testosterone to hypogonadal men reverses part of the unfavorable risk profile for the development of diabetes and atherosclerosis

Year of publication: 2011

Low total testosterone is associated with increased risk of incident type 2 diabetes mellitus in men: results from the Study of Health in Pomerania (SHIP).

There is increasing evidence suggesting that low total testosterone concentration is associated with incident type 2 diabetes mellitus (T2DM) in men. The aim of this study was to evaluate the association between total testosterone and incident T2DM in a large population-based cohort

Year of publication: 2011

Testosterone deficiency

Testosterone deficiency (TD) afflicts approximately 30% of men aged 40-79 years, with an increase in prevalence strongly associated with aging and common medical conditions including obesity, diabetes, and hypertension. A strong relationship is noted between TD and metabolic syndrome, although the relationship is not certain to be causal. Repletion of testosterone (T) in T-deficient men with these comorbidities may indeed reverse or delay their progression. While T repletion has been largely thought of in a sexual realm, we discuss its potential role in general men's health concerns: metabolic, body composition, and all-cause mortality through the use of a single clinical vignette. This review examines a host of studies, with practical recommendations for diagnosis of TD and T repletion in middle-aged and older men, including an analysis of treatment modalities and areas of concerns and uncertainty

Year of publication: 2011

Emerging cardiometabolic complications of androgen deprivation therapy.

Prostate cancer (PCa) is the most common malignancy in men. Androgen deprivation therapy (ADT) is used in the treatment of locally advanced and metastatic PCa. Although its use has improved survival in a subset of patients, it also has negative consequences. Osteoporosis, sexual dysfunction, hot flashes and adverse changes in body composition are well-known and well-studied complications of ADT. Recent studies have also found metabolic complications in these men such as insulin resistance, diabetes and metabolic syndrome. In addition, these men might also experience higher cardiovascular mortality. Studies are needed to determine the mechanism behind these complications and to employ strategies to prevent them

Year of publication: 2011

Hypogonadism in men with erectile dysfunction may be related to a host of chronic illnesses.

The prevalence of hypogonadism has been found to be increased in certain chronic illnesses, especially diabetes, hypertension and obesity. Recently, the prevalence of hypogonadism in primary care practices mirrored that in our population of men with erectile dysfunction (ED). In this study, the prevalence of hypogonadism in nearly 1000 men with ED was tabulated, using a retrospective chart review, and analyzed for association with the various contributing medical and psychological factors.

Year of publication: 2011

Effects of testosterone on Type 2 diabetes and components of the metabolic syndrome

Observations from clinical studies suggest that low serum levels of testosterone in men are often associated with obesity, insulin resistance, and metabolic compromise. Indeed, the clinical symptoms of late-onset hypogonadism are markedly similar to those of Type 2 diabetes mellitus (T2DM) and metabolic syndrome, and may share a similar pathophysiology. Observational and experimental data suggest that testosterone treatment improves a number of hallmark features of T2DM and metabolic syndrome, namely insulin resistance, obesity, dyslipidemia, and sexual dysfunction. Consequently, clinical studies have been undertaken to assess the impact of testosterone-replacement therapy in this patient group. The present article reviews the observational clinical data suggesting an association between low serum testosterone and metabolic impairment, the clinical data relating to the effects of testosterone treatment on components of the metabolic syndrome, and the randomized clinical trails that have formally investigated whether testosterone-replacement therapy provides clinical benefit to hypogonadal men with T2DM andor metabolic syndrome.

Year of publication: 2011

Screening for metabolic syndrome and testosterone deficiency in patients with erectile dysfunction: results from the first UK prospective study.

To screen patients with erectile dysfunction (ED) for the presence of metabolic syndrome (MetS), testosterone deficiency and cardiovascular (CV) risk factors, in a secondary referral centre in the UK, as men with ED have a high incidence of CV risk factors that might amount to MetS, with obesity, increased risk of coronary heart disease and type II diabetes; testosterone deficiency has also been associated with both ED and MetS. PATIENTS AND METHODS: We assessed 124 men presenting with ED between March 2007 and August 2008. Data were collected prospectively for patient demographics, risk factors associated with MetS, and hypogonadism.

Year of publication: 2011

Following the common association between testosterone deficiency and diabetes mellitus, can testosterone be regarded as a new therapy for diabetes?

Type 2 diabetes mellitus (T2DM) is increasing at epidemic proportions worldwide, representing a risk factor for cardiovascular diseases. Nowadays, hypogonadism and erectile dysfunction (ED) are considered frequent, although often under-diagnosed, complications of T2DM. Recent evidence suggests that in a diabetic population ED itself is an efficient predictor of silent coronary heart diseases. Patients with T2DM have an impaired sexual life, which is worsened by hypogonadism. Low T in T2DM is in fact associated with more severe ED, hypoactive sexual desire and low intercourse frequency. Testosterone replacement therapy (TRT) has been proven to improve sexual function in hypogonadal men. In addition, TRT improves adiposity, insulin resistance and total cholesterol. Specific studies on the effect of TRT in T2DM are scanty. This review will evaluate the contribution of low testosterone in diabetic subjects with sexual dysfunction. In addition, we have also reviewed available evidence on potential metabolic benefits of testosterone supplementation in T2DM patients

Year of publication: 2010

The dark side of testosterone deficiency: Type 2 diabetes and insulin resistance

A considerable body of evidence exists suggesting a link among reduced testosterone plasma levels, type 2 diabetes (T2D), and insulin resistance (IR). Hypogonadal men are at higher risk for T2D. Here we evaluate the relationships between testosterone, metabolic syndrome (MetS), T2D, and IR and discuss the relationships among androgen deficiency and these factors, especially as it ultimately relates to the development of cardiovascular disease and erectile dysfunction (ED). Thus, a comprehensive literature search was carried out using PubMed, and relevant articles pertinent to androgen deficiency, T2D, IR, MetS, and ED were reviewed and discussed.

Year of publication: 2009

Low testosterone levels are associated with insulin resistance in men with diabetes.

No Abstract available – check with publication for details. Click on paper for reference.

Year of publication: 2008

Androgens and diabetes in men: Results from the Third National Health and Nutrition Examination Survey (NHANES III).

Objective - Low levels of androgens in men may play a role in the development of diabetes; however, few studies have examined the association between androgen concentration and diabetes in men in the general population. The objective of this study is to test the hypothesis that low normal levels of total, free, and bioavailable testosterone are associated with prevalent diabetes in men.

Year of publication: 2007

Androgens, insulin resistance and vascular disease in men

Type 2 diabetes mellitus is increasing globally and is an established risk factor for the development of atherosclerotic vascular disease. Insulin resistance is the hallmark feature of type 2 diabetes and is also an important component of the metabolic syndrome. There is evidence to suggest that testosterone is an important regulator of insulin sensitivity in men. Observational studies have shown that testosterone levels are low in men with diabetes, visceral obesity (which is strongly associated with insulin resistance), coronary artery disease and metabolic syndrome. Short-term interventional studies have also demonstrated that testosterone replacement therapy produces an improvement in insulin sensitivity in men. Thus hypotestosteronaemia may have a role in the pathogenesis of insulin-resistant states and androgen replacement therapy could be a potential treatment that could be offered for improvements in glycaemic control and reduction in cardiovascular risk, particularly in diabetic men

Year of publication: 2005

Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men

Insulin resistance is associated with low testosterone (T) levels in men, the mechanism of which is unclear. Thus, the aim of this study was to evaluate the hypothalamic-pituitary-gonadal axis in men with a spectrum of insulin sensitivity.

Year of publication: 2005

Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes.

Type 2 diabetes is associated with lower total testosterone (T) levels in cross-sectional studies. However, it is not known whether the defect is primary or secondary. We investigated the prevalence of hypogonadism in type 2 diabetes by measuring serum total T, free T (FT), SHBG, LH, FSH, and prolactin (PRL) in 103 type 2 diabetes patients.

Year of publication: 2004

Efficacy of sildenafil citrate in treatment of erectile dysfunction: effect of type 2 diabetes

Abstract Objective: To assess efficacy of sildenafil citrate in treatment of erectile dysfunction: effect of type 2 diabetes

Year of publication: 2004

Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men.

In men, hypoandrogenism is associated with features of the metabolic syndrome, but the role of sex hormones in the pathogenesis of the metabolic syndrome and diabetes is not well understood. The authors assessed the association of low levels of testosterone and sex hormone-binding globulin (SHBG) with the development of the metabolic syndrome and diabetes in men.

Year of publication: 2004

Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency

The objective of this study was to assess the effects of oral testosterone supplementation therapy on glucose homeostasis, obesity and sexual function in middle-aged men with type 2 diabetes and mild androgen deficiency. Forty-eight middle-aged men, with type 2 diabetes, (visceral) obesity and symptoms of androgen deficiency, were included in this open-label study.

Year of publication: 2003

 

Click here to return to the main section list

The Hugh Welford Memorial library